ATARA BIOTHERAPEUTICS, INC. Depreciation
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Depreciation of $400.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-16
- ATARA BIOTHERAPEUTICS, INC. depreciation for the quarter ending 2025-12-31 was $100.00K, a 80.00% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. depreciation for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. depreciation for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. depreciation for the quarter ending 2025-03-31 was $300.00K, a 66.67% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. depreciation for fiscal 2025 was $400.00K, a 85.19% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. depreciation for fiscal 2024 was $2.70M, a 27.03% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. depreciation for fiscal 2023 was $3.70M, a 21.28% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. depreciation for fiscal 2022 was $4.70M.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $100.00K derived: sum of 2 quarters · filed 2026-03-16 | $100.00K derived: sum of 3 quarters · filed 2026-03-16 | $400.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $300.00K 10-Q · filed 2025-11-12 | $800.00K derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $300.00K 10-Q · filed 2025-08-11 | $800.00K derived: sum of 3 quarters · filed 2026-03-16 | $1.40M derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-15 | $800.00K derived: sum of 2 quarters · filed 2026-03-16 | $1.40M derived: sum of 3 quarters · filed 2026-03-16 | $2.10M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.10M derived: sum of 2 quarters · filed 2026-03-16 | $1.80M derived: sum of 3 quarters · filed 2026-03-16 | $2.70M 10-K · filed 2026-03-16 |
| 2024-09-30 | $600.00K 10-Q · filed 2025-11-12 | $1.30M derived: sum of 2 quarters · filed 2025-11-12 | $2.20M 10-Q · filed 2025-11-12 | $3.10M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $700.00K 10-Q · filed 2025-08-11 | $1.60M 10-Q · filed 2025-08-11 | $2.50M derived: sum of 3 quarters · filed 2025-08-11 | $3.40M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $900.00K 10-Q · filed 2024-05-09 | $1.80M derived: sum of 2 quarters · filed 2025-03-07 | $2.70M derived: sum of 3 quarters · filed 2025-03-07 | $3.60M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $1.80M derived: sum of 2 quarters · filed 2025-03-07 | $2.70M derived: sum of 3 quarters · filed 2025-03-07 | $3.70M 10-K · filed 2025-03-07 |
| 2023-09-30 | $900.00K 10-Q · filed 2024-11-12 | $1.80M derived: sum of 2 quarters · filed 2024-11-12 | $2.80M 10-Q · filed 2024-11-12 | $3.60M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $900.00K 10-Q · filed 2024-08-12 | $1.80M 10-Q · filed 2024-08-12 | $2.70M derived: sum of 3 quarters · filed 2024-08-12 | $3.80M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $900.00K 10-Q · filed 2024-05-09 | $1.80M derived: sum of 2 quarters · filed 2024-05-09 | $2.90M derived: sum of 3 quarters · filed 2024-05-09 | $4.30M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.00M derived: sum of 2 quarters · filed 2024-03-28 | $3.40M derived: sum of 3 quarters · filed 2024-03-28 | $4.70M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.10M 10-Q · filed 2023-11-01 | $2.50M derived: sum of 2 quarters · filed 2023-11-01 | $3.80M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $1.40M 10-Q · filed 2023-08-08 | $3.00M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $1.50M 10-Q · filed 2023-05-08 | |||
| 2017-09-30 | $250.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $472.00K derived: sum of 2 quarters · filed 2017-11-09 | $678.00K 10-Q · filed 2017-11-09 | $851.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-06-30 | $222.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $428.00K 10-Q · filed 2017-08-07 | $601.00K derived: sum of 3 quarters · filed 2017-08-07 | $732.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-03-31 | $206.00K 10-Q · filed 2017-05-04 | $379.00K derived: sum of 2 quarters · filed 2017-05-04 | $510.00K derived: sum of 3 quarters · filed 2017-11-09 | $574.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-12-31 | $173.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $304.00K derived: sum of 2 quarters · filed 2017-11-09 | $368.00K derived: sum of 3 quarters · filed 2017-11-09 | $383.00K 10-K · filed 2017-03-09 |
| 2016-09-30 | $131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $195.00K derived: sum of 2 quarters · filed 2017-11-09 | $210.00K 10-Q · filed 2017-11-09 | $237.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | $64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $79.00K 10-Q · filed 2017-08-07 | $106.00K derived: sum of 3 quarters · filed 2017-08-07 | $116.00K derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-03-31 | $15.00K 10-Q · filed 2017-05-04 | $42.00K derived: sum of 2 quarters · filed 2017-05-04 | $52.00K derived: sum of 3 quarters · filed 2017-05-04 | $57.00K derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $37.00K derived: sum of 2 quarters · filed 2017-03-09 | $42.00K derived: sum of 3 quarters · filed 2017-03-09 | $48.00K 10-K · filed 2017-03-09 |
| 2015-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $15.00K derived: sum of 2 quarters · filed 2016-11-04 | $21.00K 10-Q · filed 2016-11-04 | $23.00K derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $11.00K 10-Q · filed 2016-08-08 | $13.00K derived: sum of 3 quarters · filed 2017-03-09 | $15.00K derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-03-31 | $6.00K 10-Q · filed 2016-05-06 | $8.00K derived: sum of 2 quarters · filed 2017-03-09 | $10.00K derived: sum of 3 quarters · filed 2017-03-09 | $11.00K derived: sum of 4 quarters · filed 2017-03-09 |
| 2014-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $4.00K derived: sum of 2 quarters · filed 2017-03-09 | $5.00K derived: sum of 3 quarters · filed 2017-03-09 | $6.00K 10-K · filed 2017-03-09 |
| 2014-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $3.00K derived: sum of 2 quarters · filed 2015-11-06 | $4.00K 10-Q · filed 2015-11-06 | $5.00K derived: sum of 4 quarters · filed 2016-03-04 |
| 2014-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $2.00K 10-Q · filed 2015-08-07 | $3.00K derived: sum of 3 quarters · filed 2016-03-04 | |
| 2014-03-31 | $1.00K 10-Q · filed 2015-05-11 | $2.00K derived: sum of 2 quarters · filed 2016-03-04 | ||
| 2013-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04 | $4.00K 10-K · filed 2016-03-04 | ||
| 2013-09-30 | $3.00K 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |